A groundbreaking development in HIV prevention has arrived in Africa, offering a ray of hope in the fight against the world's highest HIV burden. The introduction of lenacapavir, an injection administered just twice a year, has been shown to reduce HIV transmission risk by an astonishing 99.9%, effectively functioning as a powerful vaccine.
In South Africa, where HIV prevalence is alarmingly high, with one in five adults affected, a research unit at Wits University has overseen the initial rollout. This initiative is supported by Unitaid, an international health agency dedicated to ensuring equitable access to medical innovations.
"The first individuals in South Africa have started using lenacapavir for HIV prevention, marking one of the first real-world applications of the six-monthly injectable in low- and middle-income countries," Unitaid stated. However, the exact number of people who received the initial doses remains undisclosed, with the drug costing a staggering $28,000 per person annually in the United States.
A broader national rollout is anticipated next year, but neighboring countries like Zambia and Eswatini have already taken the lead. Last month, these countries received 1,000 doses as part of a US program and officially launched the drug at World AIDS Day ceremonies on Monday.
In Eswatini's Hhukwini constituency, a lively public event filled with song and dance witnessed dozens lining up for the shot. Prime Minister Russell Dlamini emphasized the significance of this moment, stating, "Today marks a turning point in our national HIV response. This injection gives us fresh hope and a powerful tool to protect our citizens."
Similarly, in Zambia, hundreds marched to the Chawama township of Lusaka to commemorate the occasion. Health Minister Elijah Muchima encouraged volunteers living with HIV to visit nearby hospitals for the jab, expressing that it "brings renewed hope to young people and the vulnerable population."
However, controversy surrounds the US program, as manufacturer Gilead Sciences has agreed to provide lenacapavir at no profit to two million people in high HIV burden countries over three years. Despite South Africa's participation in clinical trials, Washington, due to policy disagreements with Pretoria, will not provide doses to the country.
Jeremy Lewin, a senior US State Department official, commented, "We encourage every country, especially those with significant means like South Africa, to fund doses for their own population."
Critics argue that the US deliveries fall short of actual requirements and that the market price is prohibitively high for most people. Eastern and southern Africa account for approximately 52% of the 40.8 million people living with HIV worldwide, according to 2024 UNAIDS data.
In Zambia alone, around 1.4 million people are living with HIV, with 30,000 new infections annually, as reported by the health ministry. Eswatini, a small kingdom with a population of 1.2 million, has approximately 220,000 people living with the virus.
Winnie Byanyima, UNAIDS executive director, criticized the limited availability of the drug, stating that drugmakers are neglecting Africa's needs. "If you don't care about those lives, at least care about the profit! Bring the drug here," she emphasized.
This development raises important questions: How can we ensure equitable access to life-saving medications? Is profit always a priority over saving lives? Join the discussion and share your thoughts in the comments.
